Pharmafile Logo

Considerations for Planning Effective and Appealing Advisory Boards: Importance of Participant Preferences

Explore our peer-reviewed article, “Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences.” Dive into key findings on HCPs’ preferences for virtual and hybrid meetings, revealing their desire for frequent interactions and the impactful use of their insights. Discover why virtual options are favored for their convenience, inclusivity, and lower environmental impact.

Pharmaceutical advisory boards and other small-group meetings with health care providers (HCPs) are important for getting feedback on new clinical trial results, competitors’ products, or educational campaigns. However, they are typically expensive and require participants to travel long distances and take time away from their work and families. For in-person meetings, there are also issues with not everyone being able to contribute as much as they want, and the exclusion of people living in remote or underserved communities is common.

These days, pharmaceutical companies have a choice between hosting meetings in person, virtually, or using a hybrid approach. In making this choice, the cost and organizer’s preference are usually key considerations, but very few people ask the participants what they prefer.

To help answer this question and elucidate the preferred meeting format, frequency, and follow-up approach, we conducted a short feedback survey among HCPs participating in virtual advisory boards in 2022 and 2023. The results were recently published in Pharmaceutical Medicine.

Key findings included that:

  • The majority of health care providers prefer virtual or hybrid pharmaceutical meetings/advisory boards over in-person-only meetings.
  • Health care providers prefer to meet at least 2–4 times per year and want to receive continuous updates on how the pharmaceutical company is using their insights.
  • Key benefits of virtual versus in-person meetings include their superior convenience and flexibility, low environmental impact, and the ability to hear from more diverse participants.

Access the full article here, titled Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences.

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Importance of Patient Advocacy in Improving Healthcare

Eva Villalba, Executive Director of the Quebec Cancer Coalition, explores the importance of patient advocacy in improving healthcare. Among many other things, we dive into how the industry can help support...

Improving Patient Care by Removing Barriers to Drug Accessibility

Alan Birch, Founder & President of Drug Access Canada, discusses all things drug access and reimbursement. Among many other things, we explore the hurdles faced by patients and drug access navigators and...

Reimagining the Patient Journey

Kimberly Tableman, CEO at Medicine X, discusses a myriad of topics related to digital transformation and patient centricity, including how digital health technologies can be used to reimagine the patient...

Environmental impact of in-person vs. virtual meetings

Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...

Leadership Lessons Learned from the Pandemic

Alok Kanti, President & CEO of Bayer Canada, discusses a variety of topics, including his experience with leading an entire organization through the COVID-19 pandemic and where he sees digital health...

Overcoming Behavioral Health Access Limitations Through Telemedicine

Phil Hirsh, PhD, Founder & Chief Executive at Synergia Integrated teleBehavioral Health; and Craig Wright, MD, Senior Physician Executive and Consultant, discuss a range of topics surrounding telemedicine and other digital health...

Commercial Execution Strategies During & After the Pandemic

Frank Armenante, Director of Commercial Execution at Novo Nordisk, discusses a range of topics, from the impact of COVID-19 on commercial operations and the digitization of Pharma to his leadership lessons...

Top 10 Reasons Why Virtual Collaboration and Medical Education Will Persist in the New Normal

Even after the pandemic is long behind us, virtual collaboration will become mainstay in Pharma.

Pharma, Technology, and Healthcare in the New Normal

Brian Canestraro, General Manager at Intercept Pharmaceuticals, discusses a range of hot topics, from Brian’s leadership lessons and tips to the impact of the COVID-19 pandemic on the way that Pharma...

Solving the Caregiver Crisis Through Technology

Curtis Khan, CEO and Founder of BookJane, discusses the ongoing caregiver crisis and how BookJane’s solutions and other digital technologies can help to close this gap. We also delve into how...